

Title (en)

USES OF THE GJB6 GENE FOR TREATING CERTAIN TYPES OF ALOPECIA INCLUDING THE CLOUSTON'S SYNDROME, AND FOR SCREENING COMPOUNDS CAPABLE OF BEING EFFICIENT IN THE TREATMENT OF ALOPECIA WITH GENETIC SUSCEPTIBILITY

Title (de)

VERWENDUNGEN DES GJB6 GENS ZUR BEHANDLUNG VON BESTIMMTEN FORMEN VON ALOPECIA INKLUSIVE DES CLOUSTON SYNDROMS UND ZUM DURCHMUSTERN VON VERBINDUNGEN DIE ZUR EFFIZIENTEN BEHANDLUNG VON ALOPECIA MIT GENETISCHER SUSZEPTIBILITÄT TAUGLICH SIND

Title (fr)

UTILISATIONS DU GENE GJB6 DANS LE TRAITEMENT DE CERTAINES ALOPECIES DONT LE SYNDROME DE CLOUSTON, ET POUR LE CRIBLAGE DE COMPOSES SUSCEPTIBLES D'ÊTRE EFFICACES DANS LE TRAITEMENT D'ALOPECIES AVEC PREDISPOSITION GENETIQUE

Publication

EP 1320603 A1 20030625 (FR)

Application

EP 01972222 A 20010927

Priority

- FR 0102997 W 20010927
- FR 0012473 A 20000929

Abstract (en)

[origin: WO0226976A1] The invention is derived from the identification of mutations in the GJB6 gene, responsible for Clouston's syndrome. The symptomatology of said syndrome suggests that the GJB6 coding for connexin 30 (Cx-30), is most probably involved also in other types of alopecia with genetic susceptibility, in particular non-pathological. Therefore, the invention concerns the GJB6 gene sequence bearing at least one of the mutations 31(G>A) and 263(C>T), responsible for Clouston's syndrome, and the use of constructs comprising the GJB6 gene, both for preparing pharmaceutical compositions for treating Clouston's syndrome and/or certain disorders of the body hair system, and for screening molecules likely to have a beneficial effect in the treatment of alopecia. The invention also concerns methods for diagnosing Clouston's syndrome.

IPC 1-7

C12N 15/12; C12Q 1/68; C12N 15/63; C12N 5/16; C12N 5/22; A61K 48/00; A61K 38/17; A61P 17/14; C07K 14/705; A01K 67/027

IPC 8 full level

A01K 67/027 (2006.01); **A61K 35/76** (2015.01); **A61K 48/00** (2006.01); **A61P 17/00** (2006.01); **A61P 17/14** (2006.01); **A61P 19/00** (2006.01); **A61P 25/02** (2006.01); **A61P 25/28** (2006.01); **A61P 27/02** (2006.01); **A61P 27/16** (2006.01); **A61P 43/00** (2006.01); **C07K 14/47** (2006.01); **C07K 14/705** (2006.01); **C12N 5/10** (2006.01); **C12N 5/22** (2006.01); **C12N 15/09** (2006.01); **C12N 15/12** (2006.01); **C12N 15/85** (2006.01); **C12Q 1/02** (2006.01); **C12Q 1/68** (2006.01); **C12Q 1/6883** (2018.01); **G01N 33/15** (2006.01); **G01N 33/50** (2006.01); **G01N 33/53** (2006.01); **G01N 33/566** (2006.01); **A61K 38/00** (2006.01)

CPC (source: EP US)

A61P 17/00 (2018.01 - EP); **A61P 17/14** (2018.01 - EP); **A61P 19/00** (2018.01 - EP); **A61P 25/02** (2018.01 - EP); **A61P 25/28** (2018.01 - EP); **A61P 27/02** (2018.01 - EP); **A61P 27/16** (2018.01 - EP); **A61P 43/00** (2018.01 - EP); **C07K 14/705** (2013.01 - EP US); **C12N 15/8509** (2013.01 - EP US); **C12Q 1/6883** (2013.01 - EP US); **A01K 2207/15** (2013.01 - EP US); **A01K 2217/00** (2013.01 - EP US); **A01K 2217/05** (2013.01 - EP US); **A01K 2227/105** (2013.01 - EP US); **A01K 2227/50** (2013.01 - EP US); **A01K 2267/0306** (2013.01 - EP US); **A61K 38/00** (2013.01 - EP US); **A61K 48/00** (2013.01 - EP US); **C12Q 2600/158** (2013.01 - EP US)

Designated contracting state (EPC)

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

DOCDB simple family (publication)

WO 0226976 A1 20020404; EP 1320603 A1 20030625; FR 2814753 A1 20020405; FR 2814753 B1 20021213; JP 2004522419 A 20040729; US 2004009505 A1 20040115

DOCDB simple family (application)

FR 0102997 W 20010927; EP 01972222 A 20010927; FR 0012473 A 20000929; JP 2002530739 A 20010927; US 40098503 A 20030327